RxDoctor Payments Data

Heidi Larson

Family · Upland, CANPI 1073501433

Payments from drug & device makers

$5,492in general payments, 2019–2025

Across 236 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Lilly USA, LLC$423
  • Novo Nordisk$414
  • AstraZeneca$384
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$357
  • GSK$238
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$5,492100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,492 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide58$72,966
JardianceEmpagliflozin53$65,188
EliquisApixaban33$43,888
OzempicSemaglutide38$37,581
FarxigaDapagliflozin Propanediol52$37,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$31,465
TrulicityDulaglutide23$26,883
TradjentaLinagliptin25$24,268
JanuviaSitagliptin Phosphate22$21,038
XareltoRivaroxaban21$16,618
LinzessLinaclotide12$13,832
Janumet XrSitagliptin Phos/Metformin Hcl16$10,910
JanumetSitagliptin Phos/Metformin Hcl16$9,535
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,094
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$423$99,84981 claims
Boehringer IngelheimJardiance, Tradjenta$215$89,45678 claims
PfizerEliquis$208$43,88833 claims
MerckJanuvia, Janumet Xr, Janumet$25$41,48454 claims
Novo NordiskOzempic$414$37,58138 claims
GSKTrelegy Ellipta, Anoro Ellipta$238$37,25041 claims
AstraZenecaFarxiga$384$37,12852 claims
AbbVieLinzess, Synthroid$208$16,14253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →